跳至主要内容
临床试验/NCT05097547
NCT05097547Unknown不适用

Contingency Management for Stimulant Use Disorders

University of Virginia0 个研究点目标入组 30 人开始时间: 2021年10月最近更新:
适应症

试验速览

阶段
不适用
入组人数
30
主要终点
stimulant abstinence

研究概览

简要总结

The invetigators' objective is to implement Medication Assisted Treatment (MAT) and contingency management in patients affected by co-occurring opioid use disorder and stimulant use disorder. Participants will continue to receive standard of care for their opioid use disorder via MAT at our Outpatient Based Opioid Treatment (OBOT) Clinic. Participants' stimulant use disorder will be targeted through contingency management, with twice weekly urine drug screens and monetary prizes in exchange for negative urine drug screens. Through regular clinic visits and the use of incentives, the investigators hope to increase treatment adherence and increase the number of negative urine drug screens in subjects struggling with co-morbid opioid use disorder and stimulant use disorder. The investigators will determine whether or not this treatment is effective in this population, versus conventional treatment (baseline therapy patients were getting through OBOT). The investigators' primary outcome measure will be stimulant abstinence duration during the twelve week study.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age 18 and older
  • Patients treated for opioid use disorder in the Outpatient Based Opioid Treatment (OBOT) Clinic and who also struggle with stimulant use disorder but failed conventional treatment (positive urine drug screen for substances other than THC and buprenorphine)
  • Ideal candidates will test positive for 3 out of 4 weeks or more prior to starting contingency management

排除标准

  • Persons under the age of 18
  • Persons not able to attend follow-up clinic visits
  • Persons not able to consent

结局指标

主要结局

stimulant abstinence

时间窗: 12 weeks

Duration of stimulant abstinence based on urine drug screens

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Nassima Ait-Daoud Tiouririne

Principal Investigator

University of Virginia

相似试验